Fibrin structure and stability have been linked to many thrombotic diseases, including venous thromboembolism. Analysis of the molecular mechanisms that affect fibrin structure and stability became possible when the crystal structure of fibrinogen was solved. Biochemical studies of natural and recombinant variant fibrinogens have examined the interactions that mediate the conversion of soluble fibrinogen to the insoluble fibrin network. These studies identified intermolecular interactions that control fibrin structure, although some critical events remain ambiguous. Studies show that fibrin structure modulates the enzymatic lysis of the fibrin network, so the molecular mechanisms that control structure also control stability. Studies show that the mechanical stability of the fibrin clot depends on the properties of the fibrin monomer, leading investigators to explore the molecular basis of the monomer's mechanical properties. The work summarized here provides insights that might allow the development of pharmaceuticals and treatments to modulate fibrin structure and stability in vivo and thereby prevent or limit thrombotic disease. (Arterioscler Thromb Vasc Biol. 2011;31:494-499.)
L arge epidemiological studies have linked fibrinogen concentration to most, if not all, thrombotic diseasescoronary artery disease, ischemic heart disease, stroke, and thromboembolic disease. 1 Smaller studies have shown that the structure and stability of fibrin clots formed from patient plasmas differ from those of clots formed from plasma from healthy individuals. [2] [3] [4] [5] Because fibrinogen concentration influences fibrin clot structure, the epidemiological correlation to concentration could logically reflect the findings in smaller studies of specific patients (Figure 1 ). The recent analysis of plasmas isolated from patients with venous thromboembolism, their first-degree relatives, and matched controls showed a correlation between fibrin network structure and the rate of clot lysis. 5 Samples from patients with idiopathic venous thromboembolism had the densest network and the slowest lysis, samples from their relatives had intermediate values, and samples from controls had the most open network and the fastest lysis. Although the implications are limited by the small number of study subjects, these results support the conclusion that the fibrin network structure is etiologic in venous thromboembolism and that genetic components likely have a significant role. Because biochemical studies link fibrin structure to fibrin stability, the fundamental question becomes: what factors control fibrin structure? Here, I enumerate molecular mechanisms that affect the structure, and I identify some issues that remain unresolved. Thereafter, I describe studies that explore the correlation between fibrin structure and stability, how the structure influences resistance to shear and to enzymatic lysis.
Fibrinogen
Fibrinogen is a 340-kDa glycoprotein composed of 2 copies each of 3 polypeptide chains, (A␣B␤␥) 2 . Fibrinogen's overall structure was originally determined by multiple electron microscopy studies, as exemplified by the studies of Weisel et al 6 Several X-ray crystal structures have confirmed this overall structure and added many significant details. [7] [8] [9] [10] These studies show that human fibrinogen is an elongated molecule with a unique center and 2 identical symmetrical distal regions ( Figure 2A ). The center, called the E region, contains the N termini of all 6 chains. The chains extend from the center as 2 coiled-coils composed of 3 chains, each coil terminating in a globular region called D. The D regions contain the carboxy termini of the B␤ and ␥ chains, called the ␤-nodules and ␥-nodules, respectively. The C-terminal segment of the A␣ chain goes through the D region, folds back to join the coiled-coil for several residues, and thereafter is not visible in the X-ray structure. Presumably, this region (A␣ residues 213 to 610) is mobile within the crystal and thus does not provide interpretable diffraction data. Other studies, including electron microscopy and nuclear magnetic resonance spectroscopy, divide this region into the ␣C connector (A␣ 221 to 391) and the ␣C domain (A␣ 391 to 610). 11, 12 
Fibrin Structure
Following vessel injury, a series of reactions occurs on the surfaces of cells at the site of injury, leading to the generation of the protease thrombin. 13 Thrombin cleaves 4 short peptides from the N termini of the A␣-and B␤-chains, releasing fibrinopeptides A and B, respectively, to generate fibrin monomers. Fibrin monomers polymerize spontaneously into a network of fibers, which stabilizes the clot. Light scattering and electron microscopy studies have shown that polymerization occurs in 2 stages, the formation of half-staggered and double-stranded protofibrils ( Figure 2B ) and the assembly of protofibrils into fibers through lateral aggregation. The final structure reflects the kinetics of these reactions and thus varies with the concentrations of fibrinogen and thrombin. 14 Fibrin polymers are stabilized by activated factor XIII (FXIIIa) catalyzed formation of ␥-glutamyl--lysyl amide bonds between monomers. These bonds link ␥ chains to form ␥-␥ dimers and ␣ chains to form ␣ polymers. Thrombin activates the FXIII zymogen, releasing the activation peptide to form the active transglutaminase. Because thrombin activates FXIII when both proteins are bound to fibrin, the conversion of fibrinogen to fibrin and the formation of covalent bonds between monomers are temporally linked. 15 Together, these processes determine fibrin structure.
Protofibril Formation
Biochemical data have consistently shown that protofibril formation is supported by 'A:a' interactions ( Figure 2B ). 13 Crystallography studies have identified the molecular basis for these interactions, and studies with natural and recombinant fibrinogen variants with changes in knob 'A' or hole 'a' show that this interaction is essential for normal polymerization. 16 -18 Early work indicated that the 'B:b' interactions support the lateral aggregation of protofibrils into fibers. 19 -21 Subsequent studies with snake venoms demonstrated, however, that nearly normal fibers form when only fibrinopeptide A is cleaved, that is, in the absence of 'B:b' interactions. 22 Studies with variant fibrinogens indicate 'B:b' interactions occur alongside 'A:a' interactions, between strands within a protofibril. 23 This suggests that 'B:b' interactions promote protofibril formation.
Lateral Aggregation
Lateral aggregation controls fiber diameter. Although recent studies indicate that 'B:b' interactions occur within protofibrils, rather than between protofibrils, one cannot conclude that 'B:b' interactions have no role in lateral aggregation. Such interactions may stabilize the protofibril intermediate and thereby shift the reaction rate to promote lateral aggregation. Alternatively the 'B:b' interactions between strands may alter the outer surfaces of the protofibrils, exposing new regions that interact to promote lateral aggregation. Thus, the role of 'B:b' remains ill defined. Other studies suggest that the ␣C domains have an important role in lateral aggregation. Lateral aggregation is impaired in the presence of ␣C-specific antibodies. 24 Moreover, electron microscopy images showed that the ␣C domains interact with one another and the E region in fibrinogen but extend from the trinodular structure in fibrin monomers. 12 On the basis of these images, Gorkun et al 12 proposed a model in which lateral association is promoted by intermolecular ␣C:␣C interactions between protofibrils. Our recent studies with recombinant fibrinogen A␣251 are consistent with this model. 25 A␣251 fibrinogen, truncated at ␣ chain residue 251, lacks the ␣C regions but otherwise is identical to normal recombinant fibrinogen. Microscopy studies showed the fibers in A␣251 clots were thinner and denser, with more branch points than fibers of normal clots. These results suggest that the ␣C domains enhance lateral aggregation to produce thicker fibers. It is important to note, however, that fiber diameters in A␣251 clots were reduced only 25% relative to normal clots. Thus, even without the ␣C domains, lateral aggregation was only modestly impaired. Doolittle and colleagues have proposed a detailed model of polymerization that includes 2 additional molecular interactions to support lateral aggregation: 1 be- Figure 1 . Correlation of fibrinogen concentration, clot structure, and thrombotic diseases. Epidemiological studies have shown that fibrinogen concentration is a risk factor for thrombotic disease. Biochemical studies have shown that fibrinogen concentration modulates clot structure, and clot structure modulates clot stability. Case-control studies link fibrin clot structure and stability to thrombotic disease. 
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Molecular Origin of Fibrin Structure and Stability tween ␤ chains, called ␤lat, and 1 between ␥ chains, called ␥lat. 26, 27 Additional studies are clearly needed to establish whether 1 or more specific interactions have a critical role in lateral aggregation.
Fiber Network
In addition to the fiber diameter, the morphology of the fibrin clot has been described by the size of the pores in the fiber network. Pore size has been assessed morphologically from the density of fibers observed in scanning electron microscopy (SEM) images. These images have the advantage that the heterogeneity (or homogeneity) of fiber density and pore size is obvious. A tightly woven network is easily distinguished from a loosely woven network. However, samples must be dehydrated and fixed for SEM, so there is a concern that sample preparation may alter the network morphology. Even with this disadvantage, SEM has proven a powerful technique to examine relative network structures. Pore size has been measured rheologically by permeability. Permeability assesses the average pore size in a fully hydrated clot. It is reasonable to conclude that permeability is a physiologically relevant measurement, as it measures accessibility of dissolved agents to the fiber network. For example, permeability likely determines access of lytic enzymes to the fibrin network. Both SEM and permeability studies have shown that pore size is correlated with fiber diameter: clots with thin fibers have smaller pores than clots with thick fibers. The molecular mechanisms that determine pore size are much the same as those that modulate protofibril formation and lateral aggregation. For example, increasing or decreasing thrombin concentrations leads to decreased or increased pore size, respectively. 28, 29 Of particular interest, recent studies performed in the presence of cells with surface generated thrombin have shown that the fibrin network structure varies with distance from the cell surface. 30, 31 The densest networks are closest to the cell surface.
FXIII Activation
Fibrin structure is also influenced by the covalent cross-links introduced by FXIIIa. The significant physiological role of this transglutaminase has been made evident by epidemiological studies that link a specific FXIII polymorphism, Val34Leu, to cardiovascular disease. 32 This polymorphism influences the rate of thrombin-catalyzed activation of FXIII and consequently the rate of cross-linking. 33, 34 Moreover, if clots were prepared from plasmas from individuals of differing genotypes, the network structures were different. 33 Both permeability measurements and SEM showed that clots from individuals homozygous for FXIII Val34 had thicker fibers and larger pores than clots from individuals homozygous for FXIII Leu34. Recent epidemiological studies have shown that the impact of this polymorphism is modulated by the fibrinogen concentration. [35] [36] [37] [38] For example, using data from the EPIC-Norfolk prospective population, Boekholdt et al found that the FXIII polymorphism alone was not associated with the risk of future coronary artery disease but that a significant interaction existed between the Leu allele and fibrinogen levels. 37 These studies show that the interplay between 2 modulators of fibrin structure, fibrinogen concentration and FXIII, markedly influences risk of thrombotic disease.
Fibrinogen Variants
Fibrin structure is also influenced by genetic variations in fibrinogen. Twin and family studies have shown that both heredity and environment affect fibrinogen levels, fiber diameter, and clot permeability. 39 Therefore, finding a direct correlation between disease and fibrinogen genotype has been elusive. Nevertheless, biochemical studies have been performed on 2 polymorphisms, A␣Thr312Ala and B␤Arg448Lys, that may modulate thrombotic disease. Studies with fibrinogen purified from homozygous individuals showed the Ala312 variant clots, which had been associated with an increased risk, had increased FXIIIa cross-linking and thicker fibers, but no difference in permeability relative to the Thr312 variant clots. 40 Studies with recombinant fibrinogens showed that Lys448 clots, associated with an increased risk, had a tighter network with thinner fibers and smaller pores compared with Arg448 clots. 41 Case-control studies have linked the level of ␥Ј fibrinogen, independent from total fibrinogen, with thrombotic disease. 42 About 10% of fibrinogen molecules contain ␥Ј chains, almost exclusively as ␥A/␥Ј heterodimers. The ␥Ј chains are encoded by an alternatively spliced ␥ chain mRNA, such that the 4 C-terminal residues of the common form, known as ␥A, are replaced with a 20-residue sequence with a large negative charge. Studies with recombinant fibrinogens showed that the ␥Ј chains altered polymerization kinetics and fibrin structure. 43, 44 SEM showed that fibers in ␥Ј/␥Ј clots are thinner than ␥/␥Ј fibers, which are similar to ␥/␥ fibers. A recent review summarizes the pleiotropic effects of this variant chain. 42
Fibrin Stability
Clot stability is regulated by both the mechanical properties of fibers and their susceptibility to enzyme-catalyzed lysis. 45 In normal hemostasis, a fibrin clot must withstand the varying pressure of pulsatile blood flow, so the clot must stretch without breaking, recoil to its original shape and size, and remain in place at the site of injury. Clot retraction, which likely is necessary for vessel patency and wound healing, requires the presence of cells and depends on the mechanical properties of fibrin fibers. Vessel patency and wound healing also depend on clot degradation by enzyme-catalyzed lysis of the fibrin matrix. 46 Fibrin itself regulates clot lysis because it enhances the activation of plasminogen and complexes with ␣2-antiplasmin.
Mechanical Properties
Recent studies have examined the molecular etiology of fibrin clot mechanics. 47 These studies showed the mechanical properties of clots depend on the mechanical properties of the individual fibrin monomers. The fibrin monomer contains 3 features that could underlie the mechanical properties of the clot: the coiled-coil connectors, the folded globular nodules, and the relatively unstructured ␣C regions. A role for coiledcoil connectors was identified in atomic force microscopy studies that measured the extension of single molecules
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Arterioscler Thromb Vasc Biol March 2011 within protofibrils 48 or small oligomers of fibrinogen 49 as a function of the force applied. Data from more recent forceextension measurements on fibrin clots were consistent with an unfolding of the coiled-coil, suggesting that this change in monomer structure is relevant within a clot. 50 Atomic force microscopy was also used to examine the strength of the 'A:a' interactions that mediate protofibril formation. 51 These experiments showed the ␥-nodule unfolds in multiple steps before dissociation of the 'A:a' interaction, suggesting that unfolding of this globular nodule could have a role in fiber mechanics. As the properties of other elastomeric fibers derive from the straightening of unstructured polypeptides, one can infer a role for the relatively unstructured ␣C regions in fibrin fiber stretching. Indeed, clots made with recombinant fibrinogen lacking the ␣C region are less stiff and show more plastic deformation than normal clots. 25 Moreover, experiments with fibrinogens from different species showed that fiber extensibility correlates with the length of this unstructured region. 52 It has been known for many years that FXIII-cross-linked clots are less susceptible to physical deformation than noncross-linked clots. 53 Recent studies with individual fibrin fibers indicate that partial cross-linking increases fiber extensibility and elasticity, whereas completely cross-linked fibers are less extensible and stiffer than un-cross-linked fibers. 54, 55 Because ␥-␥ dimers form before ␣ polymers, these data suggest that cross-links that are parallel to the fiber enhance extensibility, whereas cross-links that are perpendicular limit extensibility. Consequently, the mechanical stability of a clot in vivo could change with the extent of FXIII activity, which varies as described above.
Fibrinolysis
Clots are degraded by plasmin-catalyzed lysis of the fibrin matrix. 46 Tissue plasminogen activator (t-PA) and plasminogen bind to the surface of a fibrin clot, where t-PA cleaves plasminogen to generate the enzyme plasmin and initiate fibrinolysis. During fibrinolysis, plasmin degrades the fibrin network by cleaving specific peptide bonds in all 3 chains, releasing soluble fragments called fibrin degradation products. C-terminal lysine residues that are exposed as the fibrin network is degraded serve as additional binding sites for plasmin, thus enhancing the rate of fibrinolysis.
The rate of activation of plasminogen is faster in the presence of fibrin, relative to fibrinogen. This finding indicates that functional fibrin sites are generated during polymerization by changes in the conformation of monomers, by the juxtaposition of monomers in the polymer, or a combination of these 2. 56 Relevant sites in fibrin have been localized to segments ␣148 to 160 and ␥311 to 379, and the ␣C domain (␣392 to 610), [57] [58] [59] supporting the importance of monomer conformation. Other experiments indicate that the juxtaposition of the D nodules of 1 monomer with the E nodule of a second monomer induces conformational changes to expose the relevant sites. 60 Analysis of variant fibrinogens, each with a single substitution within ␥316 to 321, did not identify residues critical for plasmin generation but did support the conclusion that the DDE complex is critical to fibrin enhanced plasminogen activation. 61 Because pore size influences permeability and fiber density determines the concentration of bound enzymes, the fibrin network architecture regulates the distribution of lytic enzymes and thereby the rate of clot lysis. 30 Clots with a tight network (small pores and high fiber density) are lysed more slowly than clots with a loose network. Thus, the molecular mechanisms that control clot structure, as described above, modulate fibrinolysis. Of particular clinical relevance, treating fibrinogen with aspirin alters fibrin network structure in a dose-dependent manner to increase permeability. 62, 63 The rate of clot lysis parallels permeability; aspirin-treated clots have enhanced rates of clot lysis. As stated above, clots formed in plasmas isolated from patients with venous thromboembolism, from their relatives, and from normal controls show the correlation between fiber network structure and rate of lysis. 5 These studies support the conclusion that a tight fiber structure would cause delayed clot lysis, leading to thrombotic disease. Of note, recent studies have shown that fibrin structure also modulates t-PA-catalyzed activation of plasminogen; activation was more rapid on a tight network than on a loose network. 64 These studies showed that the mechanism of fibrinolysis is complex and varies with time.
Specific peptides from fibrinogen also alter clot lysis. 65 These experiments demonstrated 2 unexpected findings. First, addition of a 12-residue peptide from the ␥-nodule, WATWKTRWYSMK, did not alter fibrin assembly or lysis but rather inhibited activation of plasminogen. Second, addition of a peptide analogous to knob 'B,' GHRPY, altered fibrin assembly, leading to an altered clot structure and delayed lysis. Addition of this peptide to preformed fibrin did not alter lysis mediated by subsequent addition of t-PA and plasminogen. The authors suggest that the presence of this peptide in hole 'b' alters the interfaces between ␤C-nodules, preventing the normal lateral associations that were proposed in an earlier model of fibrin formation. Experiments with a variant fibrinogen, B␤D432A, indicate that 'B:b' interactions per se influence the rate of clot lysis. This variant cannot form 'B:b' interactions, but the B␤D432A fibrin network, measured by turbidity and SEM, is indistinguishable from normal. 66 Nevertheless, lysis of B␤D432A fibrin is enhanced relative to normal. 67 
Conclusion
In summary, epidemiological and case-control studies have shown that thrombotic disease is causally related to fibrin clot structure. The work described here provides insight into the mechanisms that control fibrin structure, which might allow development of pharmaceuticals and treatments to modulate fibrin structure in vivo and thereby prevent or limit thrombotic disease. For example, agents that impair 'A:a' interactions could alter clot structure and stability and likely enhance t-PA-induced thrombolysis. Nevertheless, many important questions remain: what interactions mediate lateral aggregation? What interactions control activation of FXIII and plasminogen on the fibrin network? What interactions link a clot's structure to its mechanical properties? Additional studies with purified reagents, plasma clots, and in vivo models are needed to characterize the molecular pathophysiology that links thrombotic disease and clot structure.
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